VivoSeq
Immunology

Lung Transplant Rejection

2

Pipeline Programs↗

1

Active Trials↗

4

Companies Involved↗

Lung Transplant Rejection is an early-stage landscape with 2 programs across 4 companies. The most active players are Kadmon, a Sanofi Company, Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Eli Lilly. 2 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

0/100

Mech. Concentration

50/100

Completion Rate

0/100

Attrition Rate

67/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

K

Kadmon, a Sanofi Company

1 program

Phase 3P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Phase 3Eli Lilly logo

Eli Lilly

1 program

Phase 3Sanofi logo

Sanofi

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 32

Belumosudil

Kadmon, a Sanofi Company

Azithromycin

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved
No programs

Analysis

Trial Status

3

clinical trials

Terminated1 · 33%
Withdrawn1 · 33%
Recruiting1 · 33%

Clinical Trials

Trial Activity

PET Assessment of Acute Lung Transplant Rejection
Terminated·WWashington University School of Medicine·N/A·NCT02204202·28 enrolled
Standard Therapy Using Tacrolimus, Mycophenolate Mofetil and Prednisone For Chronic Lung Transplant Rejection (BOS)
Withdrawn·UUniversity of Maryland, Baltimore·Phase 2·NCT04415476
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study, Followed by Open-label Extensions, to Evaluate the Efficacy of Oral Belumosudil in Adult Participants With Chronic Lung Allograft Dysfunction (CLAD) Following Bilateral Lung Transplantation
Recruiting·Sanofi logoSanofi·Phase 3·NCT06082037·180 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)